Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Rotavirus outer capsid serotype antigens (VP7 and VP4)
- Molecular classification
- Viral capsid protein, Glycoprotein (VP7), Protease-sensitive protein (VP4), Neutralization antigen
01
Overview
Rotavirus serotype antigens are viral surface proteins—primarily the glycoprotein VP7 (G antigen) and protease-sensitive protein VP4 (P antigen)—that define the serotype and strain diversity of rotavirus, a major cause of acute viral gastroenteritis in humans and animals. These antigens are responsible for eliciting neutralizing antibodies, serve as the basis for rotavirus classification, and are critical targets for vaccine-mediated immunity. Additionally, the variation and reassortment among these proteins drive the genetic and antigenic diversity of rotavirus strains worldwide.
- Other names
- Rotavirus serotypesRotavirus neutralization antigensRotavirus G and P antigensRotavirus capsid antigensVP7 glycoprotein (G antigen)VP4 protease-sensitive protein (P antigen)
02
Mechanism of action
Induction of neutralizing antibodies against VP7 (G antigen) and VP4 (P antigen), preventing virus attachment and entry into host cells
03
Biological functions
Virus attachment (VP4 binds cellular receptors)Viral entry (mediated by VP4)Induction of neutralizing antibody responseDetermination of rotavirus serotypeImmunogenicity (basis for serotype classification and vaccine design)
04
Disease associations
Infection (human and animal rotavirus gastroenteritis)Other (primary disease is viral gastroenteritis)
05
Safety considerations
Antigenic diversity and reassortment may reduce vaccine efficacy in certain populations or regionsEmergence of new serotypes through reassortment may escape immunity
06
Interacting drugs
Rotavirus vaccines (e.g., Rotarix, RotaTeq) target these antigens
07
Biomarkers
VP7 and VP4 serotype profiles (used in epidemiology and vaccine effectiveness studies)Rotavirus group classification via VP6 antigenicity
Beyond the preview
Go deeper on Rotavirus outer capsid serotype antigens (VP7 and VP4).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rotavirus outer capsid serotype antigens (VP7 and VP4).